At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effectiveness of Domperidone Versus Alginic Acid Add on Omeprazole Therapy in Omeprazole Resistance Gastroesophageal Reflux in Systemic Sclerosis
In Brief
A Phase 3 clinical trial evaluating Alginic acid, placebo (for domperidone), and 2 other interventions for Gastroesophageal Reflux Disease and 2 related conditions. Completed, enrolled 80 participants across 1 site.
Detailed Summary
The investigators purposes are to define the prevalence of omeprazole resistance gastroesophageal reflux disease (GERD) in systemic sclerosis (SSc), to compare the efficacy of omeprazole in combination with algycon versus omeprazole in combination with domperidone on the severity of reflux symptoms in omeprazole resistant GERD in SSc, and to compare the efficacy of omeprazole in combination with algycon versus omeprazole in combination with domperidone on the frequency of symptoms in omeprazole- resistant GERD in SSc.
Study Details
Timeline
Interventions
Algycon 1 tab chew tid after meal
placebo (for domperidone) 1 tab oral tid before meal
domperidone (10 mg) 1 tab oral tid before meal
placebo (for alginic acid) 1 tab chew tid after meal